Industry News

NanoVision announces license agreement, technology collaboration with OVI Lens

NanoVision Group announced it has entered into a manufacturing and distribution agreement with OVI Lens, as well as a collaboration for new technological development.

Under the agreement, OVI Lens is permitted to manufacture bandage and therapeutic contact lenses under the umbrella of NanoVision. Additionally, the agreement enables NanoVision to distribute OVI’s Quotidia Therapeutic, Quotidia Daily Aloe, Quotidia Therapeutic Aloe and Quotidia Schleral Aloe contact lenses in Asia, Europe and the Middle East on an exclusive or co-exclusive basis starting Sept. 24, according to a press release.

“Part of our growth strategy is to broaden our product portfolio and meet the growing demands of both hospitals and ambulatory surgery centers,” Dimitrii Dementiev, MD, chairman of NanoVision Group, said in the release. “This strategic alliance will enhance our manufacturing supply chain efficiency and accelerate new product development.”

NanoVision Group announced it has entered into a manufacturing and distribution agreement with OVI Lens, as well as a collaboration for new technological development.

Under the agreement, OVI Lens is permitted to manufacture bandage and therapeutic contact lenses under the umbrella of NanoVision. Additionally, the agreement enables NanoVision to distribute OVI’s Quotidia Therapeutic, Quotidia Daily Aloe, Quotidia Therapeutic Aloe and Quotidia Schleral Aloe contact lenses in Asia, Europe and the Middle East on an exclusive or co-exclusive basis starting Sept. 24, according to a press release.

“Part of our growth strategy is to broaden our product portfolio and meet the growing demands of both hospitals and ambulatory surgery centers,” Dimitrii Dementiev, MD, chairman of NanoVision Group, said in the release. “This strategic alliance will enhance our manufacturing supply chain efficiency and accelerate new product development.”